Post by PharmaShots

JAMA Oncology publishes Natera study showing Signatera MRD Test predicts overall survival and adjuvant chemotherapy benefit in patients with resected colorectal liver metastases Subscribe to our weekly newsletter and never miss a beat: https://lnkd.in/gTU62Zbz #natera #signatera #mrd #colorectalcancer #jamaoncology #galaxy #esmogi2026 #medtech #liquidbiopsy #precisiononcology #diagnostics https://lnkd.in/dr8XiMiU